Table 1.
LncRNAs are related to thyroid cancer.
| No | Approved symbol | lncRNA name | Gene locus | Expression level in patient | Molecules and pathways interacting with lncRNA in thyroid cancer | References |
|---|---|---|---|---|---|---|
| 1 | BANCR | BRAF-activated non-coding RNA | Chr. 9q21.12 | Overexpression | EZH2, EMT, the Raf/MEK/ERK signaling pathway | (67, 69) |
| 2 | PTCSC2 | Papillary thyroid carcinoma susceptibility candidate 2 | Chr.9q22 | Underexpression | MYH9 | (33) |
| 3 | PVT1 | PVT1 oncogene | Chr.8q24.21 | Overexpression | Insulin like growth factor 1 receptor, EZH2, microRNA-30a | (72, 73) |
| 4 | NEAT1 | Nuclear-enriched abundant transcript 1 | Chr.11q13.1 | Overexpression | miR-129-5p, miR-214 | (14, 15) |
| 5 | HOTAIR | Hox transcript antisense intergenic RNA | Chr.12q13.3 | Overexpression | Wnt pathway, CCND2 | (24, 25) |
| 6 | TNRC6C-AS1 | TNRC6C antisense transcript 1 | Overexpression | UNC5B, TNRC6C | (28) | |
| 7 | MEG3 | Maternally expressed gene 3 | Chr.14q32.2 | Underexpression | miR-182, Rac1 | (52, 53) |
| 8 | GAS8-AS1 | Underexpression | ATGs | (36) | ||
| 9 | PTCSC3 | Papillary thyroid carcinoma susceptibility candidate 3 | chr.14q13.3 | Underexpression | S100A4 protein, miR574-5p, Wnt/β-Catenin Signaling | (44, 45) |
| 10 | SPRY4-IT1 | SPRY4 intronic transcript 1 | Chr.5q31.3 | Overexpression | The-receptor-transduced mitogen-activated protein kinase pathway | (80) |
| 11 | GAS5 | Growth arrest specific 5 | Chr.1q25.1 | Underexpression | miR-222-3p | (86, 87) |
| 12 | H19 | H19 | Chr.15p.15.5 | Overexpression | miR-17-5p, TNFR2 | (90, 93) |
| 13 | CASC2 | Cancer susceptibility candidate 2 | Chr.10q26 | Underexpression | EMT | (95, 96) |
| 14 | MALAT1 | Metastasis-associated lung adenocarcinoma transcript 1 | Chr.11q13.1 | Overexpression | EMT, TAM | (102, 103) |